FDA OKs Late-Stage Breast Cancer Drug

Friday, 22 Feb 2013 12:27 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
U.S. health regulators said on Friday they have approved a new drug made by Roche Holding AG for some patients with late-stage metastatic breast cancer who have failed other therapies.
 
The U.S. Food and Drug Administration said it approved Kadcyla, also known as ado-trastuzumab emtansine, for patients whose cancer cells contain increased amounts of a protein known as HER2.
 
The drug's label will carry a boxed warning, the most serious possible, of the drug's potential to cause liver and heart toxicity and death. The drug can also cause life-threatening birth defects.
 
In clinical trials, patients who took the drug, known during its development process as T-DM1, survived an average of 30.9 months, compared with 25.1 months in the control group.

Special: This Small Group of Doctors are Quietly Curing Cancer

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
You May Also Like
Around the Web

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved